Spyre Therapeutics, Inc. SYRE Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on the most recent quarter.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s quick ratio?
- Spyre Therapeutics, Inc. (SYRE) reported quick ratio of 9× in Q1 2026.
- How has Spyre Therapeutics, Inc.'s quick ratio changed year-over-year?
- Spyre Therapeutics, Inc.'s quick ratio increased by 11.3% year-over-year, from 8.1× to 9×.
- What is the long-term trend for Spyre Therapeutics, Inc.'s quick ratio?
- Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s quick ratio has grown at a 7.8% compound annual growth rate (CAGR), from 9.1× to 13.3×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.